Syneron Medical and Iluminage Beauty Announce Expanded Indication for the me™ Brand of Home-use Hair Removal Systems

Syneron Medical and Iluminage Beauty Announce Expanded Indication for the me™
                    Brand of Home-use Hair Removal Systems

me™ brand now FDA cleared for permanent reduction in hair growth

PR Newswire

YOKNEAM, Israel and NEW YORK, Dec. 19, 2013

YOKNEAM, Israel and NEW YORK, Dec. 19, 2013 /PRNewswire/ --Syneron Medical
Ltd. (NASDAQ: ELOS), the global market leader in aesthetic medical devices,
and Iluminage Beauty, a leading provider of home beauty devices, announced
today that the me™ brand of home-use hair removal systems, which utilize
Syneron's proprietary elos technology, received an expanded indication for use
from the United States Food and Drug Administration (FDA) for permanent
reduction in hair growth. The me™ brand is owned and sold by Iluminage Beauty,
Syneron's global joint venture in home beauty devices.


Shimon Eckhouse, Chief Executive Officer of Syneron Medical, said, "The
additional indication for permanent reduction in hair growth for the me
home-use hair removal system is another positive milestone in the application
of our proprietary elos technology in the home-use market. It builds on its
position as the first and only FDA cleared consumer hair removal technology
that is approved for all skin tones, further differentiating it from the

Fabian Tenenbaum, Chief Executive Officer of Iluminage Beauty, said, "There
has been strong adoption of the me system in the U.S. since its initial launch
at the beginning of the year. The expanded indication, along with our new
joint venture, will position us to continue increasing awareness of the me
system among consumers and partners."

For more information on the me™ brand of home-use hair removal systems, please

About Syneron Medical
Syneron Medical Ltd. is a leading global aesthetic device company with a
comprehensive product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced solutions for a
broad range of medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, improving the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells its products
under two distinct brands, Syneron and Candela. Founded in 2000, the
corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are
located in Israel. Syneron also has R&D and manufacturing operations in the
U.S. The company markets, services and supports its products in 86 countries.
It has offices in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit

About Iluminage Beauty
Iluminage Beauty is a global joint venture in home beauty devices owned by
Unilever Ventures and Syneron Medical Ltd. It combines Unilever's global
experience in the development and marketing of consumer beauty products and
Syneron Medical's expertise in professional aesthetic device technology.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that involve risks and
uncertainties. Such forward-looking statements include the expectations, plans
and prospects for the Company, including potential increased product and
market awareness. The statements made by the Company are based upon
management's current expectations and are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. These risks and uncertainties
include market conditions and other factors beyond the Company's control and
the risk factors and other cautionary statements described in the Company's
filings with the SEC, including those described in the Company's most recent
Annual Report on Form 20-F, and the other factors described in the filings
that Syneron Medical makes with the SEC. The Company does not intend to update
these statements and undertakes no duty to any person to provide any such
update under any circumstance.

SOURCE Syneron Medical Ltd.

Contact: Hugo Goldman, Chief Financial Officer, Syneron Medical, Email:, Fabian Tenenbaum, Chief Executive Officer, Iluminage
Beauty, Email: or Zack Kubow, The Ruth Group,
646-536-7020, Email:
Press spacebar to pause and continue. Press esc to stop.